Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-02-03 00:00:00 ET · period of report 2022-02-01 · accession 0001209191-22-006779 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-02-03 | 2022-02-01 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +66.8K | 99.2K | +207% | $0 |
| 2022-02-03 | 2022-02-02 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $243.63 | -6,279 | 110.3K | -5% | -$1.53M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | A | A | 28,444 | $0.00 | 78,232 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. |
| 2 | Common | Common Stock | 2022-02-02 | F | D | 6,279 | $243.63 | 110,326 | D | — | — | |
| 3 | Common | Common Stock | 2022-02-01 | A | A | 17,445 | $0.00 | 116,605 | D | — | — | (F3) Restricted stock unit award that fully vested upon grant. |
| 4 | Common | Common Stock | 2022-02-01 | A | A | 20,928 | $0.00 | 99,160 | D | — | — | (F2) Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/17/2022. |